
Novartis is acquiring AveXis for $8.7 billion to strengthen its gene therapy unit, adding a promising but still experimental treatment targeting a fatal childhood disease.
AveXis, a small biotech based in a north Chicago suburb, is being purchased for $218 per share, or an 88 percent premium to Friday’s closing stock price, Novartis said.
8 billion for pre clinical
what ARNA WORTH now?
with 2 blockbusters in phase 3
Entrisimod and Ralinepeg?? 12 bill–16 billion??
as RCPT and Selexipeg